Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement - Test2 - elhamkhani - TriplyDB

Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement

Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement

http://www.wikidata.org/entity/Q28245267

about

Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran Reversal of oral anticoagulation Review article: Venous thromboembolism after total joint replacement Protocol in managing oral surgical patients taking dabigatran The new oral anti-coagulants and the phase 3 clinical trials - a systematic review of the literature Perioperative Management of Direct Oral Anticoagulants (DOACs): A Systemic Review Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.Fondaparinux sodium in the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism.Direct thrombin inhibitors.Correlation between trough plasma dabigatran concentrations and estimates of glomerular filtration rate based on creatinine and cystatin C.Frequency and predictors of bleeding complications associated with anti-coagulant therapy using dabigatran in Japanese patients with atrial fibrillation New oral pharmacotherapeutic agents for venous thromboprophylaxis after total hip arthroplasty Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor.Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers.Dabigatran etexilate: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery.Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions Continuous warfarin versus periprocedural dabigatran to reduce stroke and systemic embolism in patients undergoing catheter ablation for atrial fibrillation or left atrial flutter.New options in anticoagulation for the prevention of venous thromboembolism and stroke.Update on anti-coagulation in atrial fibrillation.New oral antithrombotics: focus on dabigatran, an oral, reversible direct thrombin inhibitor for the prevention and treatment of venous and arterial thromboembolic disorders Stroke Prevention in Atrial Fibrillation: Where are We Now?Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis.Medical management of venous thromboembolism: what the interventional radiologist needs to know Safety and efficacy of switching from low molecular weight heparin to dabigatran in patients undergoing elective total hip or knee replacement surgery.Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin.The Indian consensus guidance on stroke prevention in atrial fibrillation: An emphasis on practical use of nonvitamin K oral anticoagulants A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin.The clinical efficacy of dabigatran etexilate for preventing stroke in atrial fibrillation patients The modification of the thrombin generation test for the clinical assessment of dabigatran etexilate efficiency.Practical management of new oral anticoagulants after total hip or total knee arthroplasty.Emergence of new oral antithrombotics: a critical appraisal of their clinical potential.Apixaban in patients with Atrial Fibrillation: A Systematic Review Recent developments in the use of oral anticoagulants.Dabigatran etexilate: pivotal trials for venous thromboembolism prophylaxis after hip or knee arthroplasty.Dabigatran etexilate for the prophylaxis of venous thromboembolism after hip or knee replacement rationale for dose regimen.

P2860

Q26766303-9B879AA5-47FA-41BE-BDA5-A42F9B5D385A Q26799710-56B1A850-9F55-4471-9520-4606F34FA1DB Q26827835-6EA8CC3E-1547-4DE5-81B2-C650CD341131 Q27006824-1C11DC84-C390-4BEA-827D-7C556A767AC1 Q27006890-5F0761C9-E4EB-4D38-8B64-636CB64F77F5 Q27497485-7C45D58D-6DFA-4A2D-821E-5A0D32D0A279 Q28078177-6D4559DB-871E-410D-8F8F-522742A0923C Q28200198-E7E27E14-C2E0-40F7-ADAD-C3000770899E Q33381801-3B1C0E53-9FE5-4283-8C08-3EB56280B500 Q33389966-527CD226-C4A6-4789-991D-C4D4FFEAA992 Q33393692-C09587B0-3F50-444B-951E-AD41CF72D960 Q33804810-0878CD9A-44C8-46D1-8A5E-60A22FA048A9 Q33847039-21DB9819-9C46-4D99-964B-50F3247507F1 Q33891915-7321B61B-FA2A-49EA-9D94-0C2AC3A5744F Q34252907-1F379509-E27D-461F-B6F7-568A1629997C Q34285711-A3740780-AD62-4C29-86B1-01E2F399D895 Q34571082-D24FB766-56FA-4261-87A3-0E45D9BDCF84 Q34611004-54A1B599-8BBC-4242-8034-B45EFA974E7A Q34620374-3B80FE53-234C-4711-BF34-DC6F80FF5AFE Q34638063-5ADD3E8B-F3C1-40BB-81E4-BA841D3BC101 Q34666269-788609A7-3167-47F6-9F9D-A2E0B36C4871 Q34691799-852BF389-4B76-4213-9728-706B9EFBEC63 Q34906214-13DB76C1-3B4E-4913-B03E-343EC3CE9004 Q35172841-C6B58F7D-147F-4548-A46C-3AB9DD6C2FF0 Q35739671-02471EAC-5879-41EA-BADC-4485D3EE2A86 Q35811581-D647F878-AA66-4B22-87B3-1513BA8E7AA6 Q35827856-8C76BBC0-ABDE-4BA8-954F-62A3EDCFDF31 Q35948292-9BA136CF-BFCE-48D1-8DC0-DEF177973F60 Q36321989-F35CABF6-1FD6-4E96-A615-B367A2314EC4 Q36336046-15CE0BBC-42A7-4AD9-97DE-1F03E0AE49F0 Q36396649-51C99614-0418-4124-89C2-7CB411CA4FAC Q36988011-58AD0A15-8679-4C70-A3E3-E28F1C21E37D Q37014482-5608CE59-1EAB-4F0C-8319-04293D6DBE58 Q37063974-75CAA2EA-754D-4CEE-93E4-AA3C3F9DCA00 Q37338120-B7830BBF-22B5-4A2C-BD09-E211BC9A0154 Q37428883-37116ADB-C7B2-4484-AEBF-12BA0869C7E9 Q37495983-0E43523A-A140-4DDB-9AED-45251A62435B Q37528463-91D81486-FF55-4FDF-9C74-646145544F51 Q37569325-5812D49D-C855-4FBD-B629-1FE36FAFDD02 Q37583245-D51FEDEF-2AC1-4D5A-962B-8FAA44A25BB9

P2860

Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement

http://www.wikidata.org/entity/Q28245267

description

2005 nî lūn-bûn

@nan

2005 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Pharmacokinetic profile of the ...... dergoing total hip replacement

@ast

Pharmacokinetic profile of the ...... dergoing total hip replacement

@en

Pharmacokinetic profile of the ...... dergoing total hip replacement

@nl

type

label

Pharmacokinetic profile of the ...... dergoing total hip replacement

@ast

Pharmacokinetic profile of the ...... dergoing total hip replacement

@en

Pharmacokinetic profile of the ...... dergoing total hip replacement

@nl

prefLabel

Pharmacokinetic profile of the ...... dergoing total hip replacement

@ast

Pharmacokinetic profile of the ...... dergoing total hip replacement

@en

Pharmacokinetic profile of the ...... dergoing total hip replacement

@nl

P1433

Q28245267-540C1C18-3FE2-458B-A64F-090BA896ABBD

P1476

Q28245267-1CC10AC2-0E24-4F3E-9F76-A66F3E4CBA04

P2093

Q28245267-12E2C62B-11E4-4EB6-9744-6612A8A01E5F

Q28245267-8047BCB8-C1C6-48D9-97D3-ED665FD03443

Q28245267-A793BD72-61D8-471D-9DE2-0574EC68DF9F

Q28245267-BE95A61D-4C41-47B5-929E-0FED612BB1A5

Q28245267-C40B8F0A-3311-4DFD-A0D3-59DD1B82381B

Q28245267-CC4DCEEF-8A12-4FC4-B678-47BFDE743846

Q28245267-EDF86812-75E3-4289-9D1A-F21BBF0B818A

P2860

Q28245267-0E2F7EF6-66BE-4AD7-A601-B1A74A643D69

Q28245267-1DAA1566-955F-490B-8860-28A45DC6955C

Q28245267-3E671D7A-7013-4D8C-9A99-9537B964A40B

Q28245267-4DBE5D29-E6CC-40AC-93F0-571748721A71

Q28245267-5882289F-A3D7-4444-BFBE-BA0AC4068132

Q28245267-8AF755FB-D667-4F2F-B6E3-096224C03EBD

Q28245267-A160D747-BEA9-409A-BACE-511FD116EE66

Q28245267-A338F9F1-7C42-4200-BFEF-82E54D60A994

Q28245267-B4F5AF07-E502-4C19-803A-2945A9740784

Q28245267-D93E2663-8AF7-4380-8928-E239168ABBEF

P304

Q28245267-3872BB7C-9BCA-4B8C-8C6A-628C49D48CF4

P31

Q28245267-14A954FD-1245-42A4-B39C-18A690C97FEB

P3181

Q28245267-C971F2F7-1FB4-4633-99C6-1DD55D5C3A31

P356

Q28245267-A87B78D9-21FD-4BC6-A2AC-D1C5C498FACF

P407

Q28245267-9377412B-1BB5-4D12-99F9-B1ECEBB42BA4

P433

Q28245267-49E3DDC3-74B7-4610-871A-4AFEFD1DF1E4

P478

Q28245267-FA13DCF1-E8FF-4DF4-82F5-903F41C7033B

P50

Q28245267-8DA22DCA-7F18-4F6E-B41C-2841953E44C2

P577

Q28245267-EE416C57-6FBA-4B59-BFE3-6B32EE972728

P5875

Q28245267-10A6A3A1-C5A5-4F73-87EF-42353F775F9B

P698

Q28245267-B7AF83CC-8371-4F9A-A5E2-F7BFAD284866

P921

Q28245267-5D8B47A6-A626-4C38-B0C2-BD19CE7896B2

Q28245267-C7B63E2C-9B94-4D66-A7BF-81507B43CC1C

P3181

P356

0091270005274550

P1433

The Journal of Clinical Pharmacology

P1476

Pharmacokinetic profile of the ...... dergoing total hip replacement

@en

P2093

Bengt I Eriksson

http://www.w3.org/2001/XMLSchema#string

Hildegard Stähle

http://www.w3.org/2001/XMLSchema#string

Joachim Stangier

http://www.w3.org/2001/XMLSchema#string

Karin Rathgen

http://www.w3.org/2001/XMLSchema#string

Lennart Ahnfelt

http://www.w3.org/2001/XMLSchema#string

Ola E Dahl

http://www.w3.org/2001/XMLSchema#string

Robbyna Svärd

http://www.w3.org/2001/XMLSchema#string

P2860

Structure-based design of novel potent nonpeptide thrombin inhibitors

Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

A comparison of the Two One-Sided Tests Procedure and the Power Approach for assessing the equivalence of average bioavailability

The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Management of venous thromboembolism: past, present, and future.

A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial.

Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I.

Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies.

Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial.

Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin Trial Investigators.

P304

555-63

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

249597

http://www.w3.org/2001/XMLSchema#string

P356

10.1177/0091270005274550

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

45

http://www.w3.org/2001/XMLSchema#string

P50

P577

2005-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7904943

http://www.w3.org/2001/XMLSchema#string

P698

15831779

http://www.w3.org/2001/XMLSchema#string

P921

pharmacokinetics